Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AMRI Names DMPK Director | Contract Pharma

What are you searching for?

Sign in
Breaking News

AMRI Names DMPK Director

Jensen will work to enhance discovery biology and chemistry platform

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles Jensen, Ph.D., has been appointed director of Drug Metabolism and Pharmacokinetics (DMPK) at AMRI. He reports to Bruce J. Sargent, Ph.D., senior vice president of Drug Discovery.

Dr. Jensen has more than 20 years of experience working in the fields of drug metabolism and toxicology in the pharmaceutical industry. He spent 15 years at Eli Lilly and Co., where he ultimately became senior study director for drug development services for in vitro technologies. Prior to Lilly, Dr. Jensen worked for RTI Health Solutions, where he established a full-service in vitro DMPK-toxicology lab and developed a robust intestinal permeability/Pgp transport model.

“At AMRI, we consider early ADMET profiling and pharmacokinetic analysis to be crucial components of the drug discovery process, and we are excited to have Dr. Jensen join us with his substantial experience in these fields. His DMPK expertise adds additional depth to AMRI’s leading drug discovery team and will help position the company as it expands its involvement with fully integrated discovery biology and chemistry programs,” said Dr. Sargent.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics